London, Feb 4, 2026, 09:42 (GMT) — Regular session
- Haleon shares climbed roughly 1%, hitting 388.1 pence in early trading
- The company’s most recent voting-rights filing pegged voting shares at 8.91 billion as of Jan. 31
- Investors will turn to Haleon’s full-year results, due Feb. 25
Haleon (LSE:HLN, NYSE:HLN) shares edged up roughly 1% in early London trading on Wednesday. The stock climbed 0.96% to 388.1 pence, putting the consumer healthcare firm’s market cap near £34.6 billion, based on delayed data from the London Stock Exchange. (Lse)
Investors are gearing up for Haleon’s full-year results on Feb. 25, a key date for FTSE 100 defensive stocks. The company will also release a first-quarter trading update on April 29. (Haleon Corporate)
On Monday, Haleon issued an update on its share capital in a routine “total voting rights and capital” statement. The filing revealed 8,952,353,648 shares outstanding as of Jan. 31, with 45,557,120 shares held in treasury. That leaves 8,906,796,528 shares carrying voting rights. (Investegate)
Treasury shares are the stocks a company keeps after buybacks and they come without voting rights. The voting-rights figure is crucial since investors rely on it to determine if they need to report changes in their holdings under UK transparency rules.
Haleon kicked off trading at 381.7 pence, fluctuating between 380.9 and 388.3 pence by 0928 GMT, with roughly 1.0 million shares changing hands, according to LSEG data. The stock’s beta, indicating its volatility compared to the broader market, sat near 0.38. (Investorschronicle)
The wider UK market showed volatility Tuesday as the FTSE 100 slipped from its record peak. Tech-related stocks faced a steep selloff, dragging sentiment down ahead of the Bank of England’s policy meeting scheduled for later this week. (Reuters)
Healthcare stocks slid across Europe Wednesday following Novo Nordisk’s forecast of a year-on-year decline in sales and operating profit for 2026, weighing on the sector. Haleon, leaning more towards consumer staples than prescription drugs, bucked the trend early in the session. (Reuters)
Haleon faces a key moment with its Feb. 25 report. Investors will zero in on demand trends in core areas like oral health, vitamins, and pain relief, along with any updates on margins and cash flow.
Yet, a run-up before results can vanish fast. If 2026 guidance hints at slower volumes, tighter margins, or currency headwinds, shares might slip. The market’s already valuing safer bets, after all.
Following the Feb. 25 results, Haleon’s next key date is its trading update on April 29. Investors will focus on management’s outlook for the year, beyond just the top-line figures.
